Camp4 Therapeutics Corporation (CAMP)

Market Cap	37.27M
Revenue (ttm)	652,000
Net Income (ttm)	-51.79M
Shares Out	20.15M
EPS (ttm)	-11.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	174,342
Open	1.840
Previous Close	1.780
Day's Range	1.840 - 1.840
52-Week Range	1.760 - 12.300
Beta	n/a
Analysts	Buy
Price Target	19.33 (+944.87%)
Earnings Date	Nov 21, 2024

About CAMP

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was inco...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2024
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CAMP
• Website: https://www.camp4tx.com

Financial Performance

In 2024, Camp4 Therapeutics's revenue was $652,000, an increase of 86.29% compared to the previous year's $350,000. Losses were -$51.79 million, 5.07% more than in 2023.

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for CAMP stock is "Buy." The 12-month stock price forecast is $19.33, which is an increase of 944.87% from the latest price.

Price Target

$19.33

(944.87% upside)

Analyst Consensus: Buy